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Toll-like receptors (TLR) are crucial players in the innate immune response to microbial invaders. These receptors
are expressed on immune cells, such as monocytes, macrophages, dendritic cells, and granulocytes. Importantly,
TLR are not only expressed by peripheral blood cells, but their expression has been demonstrated in airway
epithelium and skin, important sites of host–pathogen interaction. Host cells expressing TLR are capable of rec-
ognizing conserved pathogen-associated molecular patterns, such as lipopolysaccharide and CpG DNA, and their
activation triggers signaling pathways that result in the expression of immune response genes and cytokine
production. As TLR are instrumental in both launching innate immune responses and inﬂuencing adaptive im-
munity, regulation of TLR expression at sites of disease such as in leprosy, acne, and psoriasis may be important in
the pathophysiology of these diseases. Furthermore, since TLR are vital players in infectious and inﬂammatory
diseases, they have been identiﬁed as potential therapeutic targets. Indeed, synthetic TLR agonists such as
imiquimod have already established utility in treating viral pathogens and skin cancers. In the future, it seems
possible there may also be drugs capable of blocking TLR activation and thus TLR-dependent inﬂammatory re-
sponses, providing new treatment options for inﬂammatory diseases.
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In response to pathogen exposure, a host employs both the
innate and adaptive arms of the immune system to protect
against infection. The innate immune response utilizes both
physical barriers such as skin and mucosal epithelium as a
means of avoiding infection and rapid cellular responses
enacted by dendritic cells (DC), monocytes, natural killer
cells, granulocytes, and epithelial cells to protect a newly
infected host. These cells express pattern recognition re-
ceptors that mediate responses to pathogen-associated
molecular patterns (PAMP) that are conserved among mi-
croorganisms. Human Toll-like receptors (TLR) are one such
family of pattern recognition receptors capable of initiating
innate immune responses and influencing subsequent
adaptive immune responses (Medzhitov et al, 1997). Cur-
rently, 10 TLR are known to be expressed in humans, and
the microbial ligands for many of these receptors have been
identified (Fig 1). The ligands include molecules uniquely
found in microbes such as bacterial cell wall components.
More specifically, TLR4 mediates host responses to bacte-
rial lipopolysaccharide (LPS) from Gram-negative bacteria
such as Escherichia coli, whereas TLR2 mediates respons-
es to peptidoglycan from Gram-positive bacteria such as
Staphylococcus aureus (Poltorak et al, 1998; Yoshimura
et al, 1999). In addition, TLR2/1 heterodimers mediate
responses to tri-acylated lipoproteins, and TLR2/6 het-
erodimers mediate responses to di-acylated lipoproteins
(Brightbill et al, 1999; Ozinsky et al, 2000). Not all TLR,
however, mediate innate responses to components of bac-
terial cell walls. For instance, TLR9 mediates the response
to unmethylated CpG DNA found in bacterial genomes,
whereas TLR3 mediates the response to viral double-
stranded RNA (Hemmi et al, 2000; Alexopoulou et al, 2001).
Furthermore, TLR5 is involved in mediating the host re-
sponse to bacterial flagellin, and recently single-stranded
RNA was identified as the ligand for TLR8 in humans and
TLR7 in mice (Hayashi et al, 2001; Diebold et al, 2004; Heil
et al, 2004).
TLR are transmembrane proteins with the extracellular
portion composed of leucine-rich repeats, whereas the in-
tracellular portion shares homology with the cytoplasmic
domain of the IL-1 receptor. When TLR are activated by
ligand exposure, the intracellular domain of the TLR may
trigger a MyD88-dependent pathway that ultimately leads to
the nuclear translocation of the transcription factor NFkB.
NFkB then acts to modulate expression of many immune
response genes (Takeda et al, 2003).
In MyD88-dependent signaling, MyD88 interacts with the
Toll/IL-1 receptor (TIR) domain of the cytoplasmic portion of
the TLR (Medzhitov et al, 1998). This interaction then facil-
itates MyD88 association with IL-1 receptor-associated
kinase (IRAK), a serine–threonine kinase, which in turn
activates tumor necrosis factor receptor-activated factor 6
(TRAF6) (Suzuki et al, 2002). TRAF6 may then activate the
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IKK complex that leads to the phosphorylation and conse-
quent degradation of IkB. Once IkB is ubiquitinated and
degraded, the transcription factor NFkB is available for nu-
clear translocation (Woronicz et al, 1997).
Although an important player in innate immune respons-
es, MyD88 is not required for recognition of some microbial
ligands, and not all TLR signaling is completely MyD88-
dependent (Fig 2). There is some evidence that TLR3 and
TLR4 also trigger a MyD88-independent pathway that in-
volves IRF-3 to ultimately produce interferon (IFN)-b (Doyle
et al, 2002). Subsequent studies have revealed that the
TLR4-mediated activation of IRF-3 involves the adaptor
proteins TRIF and TRAM (Hoebe et al, 2003; Yamamoto
et al, 2003a). Likewise, TRIF was also found to mediate
TLR3-dependent activation of IRF-3, but TRIF has also
been shown to mediate the TLR3-dependent MyD88-inde-
pendent activation of NFkB through TRAF6 (Yamamoto
et al, 2003b; Jiang et al, 2004). Furthermore, there are other
receptors that act independently of MyD88 to recognize
conserved microbial patterns. These include Nod1 and
Nod2, which are intracellular receptors for peptidoglycan
that act independently of TLR and MyD88 to activate NFkB
(Girardin et al, 2003a, b; Inohara and Nunez, 2003).
Consequences of TLR Activation
TLR activation contributes to host inflammatory responses.
The activation of NFkB allows for transcription of immuno-
modulatory genes, including the genes for various cytokines
and chemokines. The production of cytokines and chemo-
kines in turn triggers inflammation through the recruitment
of host immune cells and activation of antimicrobial de-
fenses. Although this may aid the host in clearing an infec-
tion, inflammation triggered through TLR may also harm the
host through the damage of host tissues or the develop-
ment of septic shock.
TLR activation is also involved in the phagocytosis of
pathogens by host cells. TLR have been shown to sample
phagosomal contents and trigger production of inflamma-
tory cytokines after activation by TLR ligands within the
phagosome (Underhill et al, 1999). More recently, TLR ac-
tivation has also been shown to trigger internalization of
pathogens as well as induce the maturation of host phago-
somes (Blander and Medzhitov, 2004). The mechanism be-
hind TLR-induced phagocytosis has been shown to involve
MyD88, IRAK4, and p38, resulting in the up-regulation of
scavenger receptors (Doyle et al, 2004). Thus, TLR activa-
tion promotes phagocytosis of pathogens and inflammatory
responses to phagosome contents as well as the matura-
tion of phagosomes, allowing for the killing of phagocytosed
bacteria.
Another consequence of TLR activation is the triggering
of direct antimicrobial pathways that promote the release of
non-specific antibacterial molecules such as antimicrobial
peptides. For example, primary human airway epithelial
cells demonstrate increased b-defensin-2 production in
response to TLR2 agonists, and LPS also stimulates in-
creases in b-defensin-2 expression by tracheobronchial
epithelium (Becker et al, 2000; Hertz et al, 2003; Wang
et al, 2003). Furthermore, stimulation of an in vitro recon-
structed epidermis with LPS has been shown to increase
keratinocyte production of human b-defensin-2 mRNA by 4-
fold (Chadebech et al, 2003). Interestingly, antimicrobial
peptides are not only induced through TLR, but they may
also activate cells through TLR. For instance, murine b-de-
fensin-2 has been shown to activate DC through TLR4
(Biragyn et al, 2002). Thus, TLR activation is capable of
promoting antimicrobial peptide production, and the release
of these peptides may trigger more TLR activation. Impor-
tantly, TLR activation can also lead to the production and
release of reactive oxygen and nitrogen species that aid in
killing intracellular pathogens such as Mycobacterium
tuberculosis in mice (Thoma-Uszynski et al, 2001).
Figure 1
Human Toll-like receptors display specificity in their recognition of pathogen-associated molecular patterns and/or synthetic compounds.
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Furthermore, TLR activation facilitates and instructs the
development of adaptive immune responses. One way TLR
facilitate adaptive immunity is by increasing the levels of
expression of co-stimulatory molecules such as CD80 and
CD86 on DC, allowing the DC to more effectively activate T
cells (Tsuji et al, 2000; Michelsen et al, 2001). Another av-
enue through which TLR activation influences adaptive im-
munity is through the production and release of cytokines.
An important aspect of cytokine production is that the spe-
cific cytokines produced may instruct differentiation of T
cells into Th1 or Th2 subsets, which guide the pattern of
adaptive response the host will launch against the patho-
gen. For instance, human monocyte-derived DC stimulated
with lipopeptide from M. tuberculosis secrete IL-12 over IL-
10, skewing the host’s adaptive immune response toward a
Th1 pattern, characterized by a cellular, cytotoxic T cell re-
sponse (Thoma-Uszynski et al, 2000). In contrast, activation
of an adaptive Th2 immune response by cytokines such as
IL-10 and IL-4 is characterized by the involvement of B cells
and antibody production. Thus, the activation of TLR on DC
serves not only to activate an innate immune response to a
pathogen but also to instruct the pattern of the host’s en-
suing adaptive immune response.
TLR activation may also lead to apoptosis. LPS has been
shown to induce apoptosis through TLR4 (Choi et al, 1998).
Furthermore, the 19 kDa lipoprotein from M. tuberculosis
has been shown to trigger apoptosis in macrophages, and
activation of TLR2/6 with Mycoplasmal lipoproteins has also
been shown to induce apoptotic cell death (Lopez et al,
2003; Into et al, 2004). This activation of TLR2 with bacterial
lipoproteins has been shown to signal apoptosis through
MyD88, Fas-associated death domain protein, and caspase
8 (Aliprantis et al, 2000). Importantly, the induction of
apoptosis in infected cells through TLR ligands may help
the host in eliminating the infection.
TLR Expression in Skin
As mentioned earlier, TLR are expressed by various cells of
the innate immune system such as monocytes, macroph-
ages, DC, and granulocytes. Moreover, as TLR are key
players in the innate response to pathogens, the expression
and function of TLR at sites of host-pathogen interaction is
critical for host defense. This allows recognition of patho-
gens before they invade the bloodstream or the tissues of
Figure 2
Human Toll-like receptor activation triggers MyD88-dependent and MyD88-independent signaling pathways resulting in gene transcription.
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internal organs. This is indeed the case as TLR expression
has been demonstrated in the epithelial cells of the airway
and gut. Given that the skin is another crucial interface for
host encounters with microbial invaders, it seems appro-
priate that the skin express TLR to accomplish its job as a
barrier to infection.
One study has demonstrated that normal keratinocytes
express TLR1, 2, and 5 (Baker et al, 2003). This study uti-
lized punch biopsies from regions of normal skin in psoriasis
patients and normal breast skin obtained from donors with
no known skin diseases. Antibody staining of the biopsies
demonstrated cytoplasmic TLR1 and TLR2 expression
throughout the epidermis with TLR2 staining most strongly
on basal keratinocytes. The basal layer also demonstrated
TLR5 staining. Thus, it appears that keratinocytes in differ-
ent layers of the epidermis may express different TLR; as
keratinocytes mature as they progress from the basal layer
to the surface of the skin, their patterns of TLR expression
may also change.
Although not detected in the study previously discussed,
other studies report expression of TLR4 on keratinocytes.
Pivarcsi et al (2003) demonstrated TLR2 and TLR4 mRNA
and protein expression in cultured human epidermal kera-
tinocytes obtained from the skin of healthy individuals. Also,
antibody staining of skin sections demonstrated the pres-
ence of TLR2 and TLR4 throughout the epidermis. Notably,
the ability of Pivarcsi et al to detect TLR4 corroborates an
earlier study that utilized cultured human keratinocytes de-
rived from foreskin. Song et al (2002) detected TLR4 mRNA
through both northern blot and quantitiative PCR analyses,
and this TLR4 expression was shown to increase in re-
sponse to treatment with LPS. In addition, flow cytometry
revealed surface TLR expression on these keratinocytes,
and immunostaining with TLR4 monoclonal antibody was
positive. Moreover, this group demonstrated that the LPS-
induced IL-8 expression by these keratinocytes was TLR4
dependent. Most recently, Mempel et al (2003) reported
that cultured primary human keratinocytes expressed
TLR1,2,3,5, and 9, but TLR4,6,7, and 8 were undetectable.
These conflicting reports make it unclear if keratinocytes
constituitively express TLR4. Therefore, it seems additional
studies are needed to clarify TLR expression in keratin-
ocytes.
Effector Functions of Keratinocyte
TLR Activation
Studies with keratinocytes have not only demonstrated the
expression of TLR, but they have also shown the ability of
keratinocytes to activate innate immune responses through
their TLR. Stimulation with Candida albicans or heat-killed
M. tuberculosis, which possess TLR-stimulatory molecules,
strongly induced NFkB in cultured keratinocytes suggesting
that keratinocytes are capable of launching TLR-mediated
responses (Pivarcsi et al, 2003). Furthermore, Mempel et al
found stimulation of keratinocytes with Staphylococcus au-
reus caused translocation of NFkB and subsequent in-
creased production of IL-8 and iNOS. This inflammatory
response was found to be TLR2 dependent (Mempel et al,
2003). Thus, TLR are not merely present on keratinocytes
but may be active participants in cutaneous defense
through triggering NFkB activation and thus production of
cytokines and chemokines. Induction of chemokines and
cytokines through TLR activation promotes the recruitment
of immune cells out of the circulation to sites of infection,
such as the skin, and the modulation of immune cell
behavior.
TLR-activated keratinocytes are also capable of modu-
lating the host’s adaptive immune response. Lebre et al
(2003) demonstrated that supernatants of TLR-stimulated
keratinocytes induced the maturation of human monocyte-
derived immature DC. These now-mature DC were found
to promote Th1 immune responses from naı¨ve T cells. Thus,
keratinocytes may be able to influence the development of
Th1 or Th2 adaptive immune responses to cutaneous path-
ogens. Furthermore, this suggests that keratinocytes,
through their activation of DC, may play an important role
in inflammation mediated by T cells in the skin.
In summary, keratinocytes play dynamic roles in host
defense that extend beyond their role as a physical barrier.
Keratinocytes have been shown to produce cytokine and
antimicrobial peptides, recruit neutrophils, and kill microbes
such as C. albicans. It appears now that many of these
abilities are due to the activation of their TLR.
TLR Expression: When Less is Better
Although TLR expression at sites of host–pathogen inter-
action likely serves to protect the host from pathogens,
unnecessary immune responses to commensal bacterial
may harm the host. This concept is illustrated by studies of
TLR expression in Langerhans cells (LC), unique DC found
in the epidermis. In contrast to DC, LC have been shown to
respond differently to microbial TLR ligands. For example,
LPS is capable of inducing the maturation of DC but not
LC. Moreover, stimulation with LPS leads to the upregu-
lation of CD80, CD86, and HLA-DR on DC but not LC. One
group linked this relative unresponsiveness of LC to lower
levels of TLR expression on the LC (Takeuchi et al, 2003).
More specifically, this group could not detect mRNA for
TLR4 in LC, and the amount of mRNA encoding TLR2
found in LC was demonstrably less than that found in DC.
The authors propose the diminution of TLR expression on
LC found in skin, as compared with DC, may explain why
commensal bacteria do not continuously trigger inflamma-
tory responses in the skin. More recently, another group
has also demonstrated differences in TLR expression and
activation between LC and DC (Mitsui et al, 2004). LC were
found to have much lower levels of TLR4 on their surfaces
as compared with DC, and unlike DC their level of TLR4
expression was not upregulated after stimulation with LPS.
In addition, stimulation with ligands for TLR2,4, and 9
matured splenic DC but not LC. Taken together these
results suggest that the differences in expression and
activation of TLR on LC may potentially explain why com-
mensal bacteria do not continuously trigger inflammation
in skin; however, greater knowledge of the role of TLR
on LC is warranted before this theory may be considered
a fact.
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TLR and Dermatological Disease
Leprosy Leprosy, a disease caused by infection with the
organism mycobaterium varies widely in its clinical presen-
tation, which can be correlated with the type of immune
response the host has launched against M. leprae. The
tuberculoid form of the disease is characterized by localized
infection, granulomatous lesions, and the expression of
type 1 cytokines that promote cell-mediated immunity. On
the other end of the spectrum is the lepromatous form of the
disease that is characterized by disseminated infection,
disfiguring nodular lesions, and the expression of type 2
cytokines that promote a humoral immune response. A re-
cent study demonstrated that heterodimers of TLR2/1 were
activated by killed M. leprae (Krutzik et al, 2003). Since
earlier studies indicate TLR2/1 heterodimers recognize tri-
acylated lipoproteins, the genome of M. leprae was
scanned to identify putative lipoproteins. Further experi-
ments revealed that two lipoproteins, identified as 19 and
33 kDa, were capable of both monocyte and DC activation.
Furthermore, the staining of skin lesions revealed that pa-
tients with the tuberculoid form of the disease more strongly
expressed TLR2 and TLR1 within the lesion as compared
with patients with lepromatous leprosy, suggesting that le-
promatous patients may not be as able to activate cellular
immune responses. Thus, in leprosy, the activation and
regulation of TLR2 and TLR1 at the site of disease may
contribute to the host’s defense against M. leprae.
Responses launched through activated TLR, however,
may not always be beneficial to the host. TLR activation
may not only activate immune response genes but also
apoptosis genes (Aliprantis et al, 2000). Therefore, the
apoptosis pathway may also be important in the pathogen-
esis of infectious diseases. For instance, TLR2 expression
was demonstrated on the surface of primary human
Schwann cells. Furthermore, activation of primary Schwann
cells with a synthetic peptide of the 19 kDa lipoprotein of
M. leprae increased the number of apoptotic Schwann cells
(Oliveira et al, 2003). Schwann cells found in leprosy skin
lesions were shown to express TLR2, and apoptotic
Schwann cells were demonstrated within the lesions. Thus,
lipopeptides from M. leprae may promote TLR-induced
apoptosis in Schwann cells. In light of these studies, the
nerve injury observed in leprosy patients appears to be a
consequence of the innate immune response to M. leprae.
Acne vulgaris Acne vulgaris is characterized clinically by
non-inflammatory comedones and inflammatory papules,
pustules, and nodules. The histological picture of an in-
flammatory lesion demonstrates follicular rupture, ne-
utrophils and lymphohistiocytic infiltrates surrounding the
pilosebaceous unit, and potential scar formation. In inflam-
matory acne, the Gram-positive microbe Propionibacterium
acnes contributes to inflammation by inducing cytokine se-
cretion and also releases substances such as proteases
and hyaluronidases that contribute to tissue injury. Studies
from our lab have shown that P. acnes induces IL-12 and IL-
8 release from primary human monocytes that may be im-
portant in inflammatory acne, and studies of gene-disrupted
mice have also demonstrated that this inflammatory re-
sponse is TLR2 mediated (Kim et al, 2002). Importantly,
TLR2 expression was also demonstrated in biopsied acne
lesions, particularly in perifollicular regions, and the quantity
of TLR2-positive cells detected increased with the increas-
ing age of the lesion. This demonstration of TLR2 expres-
sion at the site of disease indicates that the inflammation
triggered through TLR2 is important in the pathogenesis
of acne.
Psoriasis Psoriasis is a chronic inflammatory skin disease
mediated by T cells and characterized clinically by hyper-
proliferation of the epidermis (Baker et al, 1984; Hammar
et al, 1984). It is a disease of unknown etiology, although
several microorganisms have been implicated as triggers
capable of initiating or exacerbating the disease (Rosenberg
et al, 1994; Kanda et al, 2002; Perez-Lorenzo et al, 2003).
Based on these implications, research into the modulation
of TLR in psoriatic lesions has been pursued. One study
compared TLR expression in lesional and non-lesional ex-
tensor forearm skin biopsies of untreated chronic plaque
and guttate psoriasis patients (Baker et al, 2003). No dra-
matic differences in TLR expression were found. The re-
searchers, however, noted that TLR2 appeared to be more
strongly expressed in the upper epidermis of psoriasis pa-
tients, whereas TLR2 was more strongly expressed in the
basal layers of normal and non-lesional skin. Also, TLR5
expression was reduced in basal keratinocytes of lesions as
compared with normal skin. Another group of investigators
found that the basal keratinocytes of psoriatic skin demon-
strated a strong and diffuse expression of TLR1 (Curry et al,
2003). Since psoriasis lesions display marked epidermal
thickening and mitotic activity above the basal layer of cells,
these results may suggest that the differences in TLR
expression in psoriatic lesions versus normal skin can
be explained by the differences in age/maturity of the
keratinocytes within the respective layer; as the proliferation
of keratinocytes in psoriasis occurs above the basal layer,
cells in the upper layers of the epidermis may be younger
and exhibit less mature phenotypes with respect to TLR
expression. Furthermore, the differential expression of TLR
across the layers of the epidermis may have a functional
role in contributing to host immune defense in skin. Impor-
tantly, these subtle variances in TLR expression within
psoriatic lesions have not yet been linked to the etiology or
pathogenesis of the disease.
Lyme disease Lyme disease is caused by infection with
the spirochete Borrelia that is transmitted to humans via
Ixodes ticks. Early stage Lyme disease is recognized by the
skin lesion erythema migrans, a dermal inflammatory re-
sponse to the spirochete. Without treatment, subsequent
dissemination of the infection may occur and can lead to
arthritis and carditis. Prior vaccination against Lyme disease
or timely antibiotic treatment of erythema migrans can,
however, prevent the development of such sequelae.
One of the antigens of Borrelia burgdorferi capable of
stimulating an immune response is the outer surface protein
A lipoprotein (OspA). One study demonstrated that TLR2
and TLR6 are necessary for OspA-induced NFkB activation
(Bulut et al, 2001). More recent studies, however, have
demonstrated that TLR2/1 heterodimers are necessary to
recognize OspA and launch an effective immune response
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to B. burgdorferi. Indeed, one study examining the effec-
tiveness of the Lyme disease vaccine (recombinant OspA)
identified individuals with low antibodies to OspA after vac-
cination (Alexopoulou et al, 2002). The macrophages of
these subjects, although expressing normal levels of TLR2,
had low expression of TLR1 on their surfaces. Furthermore,
mice deficient in TLR2 or TLR1 also demonstrated low an-
tibodies to OspA after vaccination. Moreover, the recogni-
tion of OspA by TLR2/1 heterodimers follows the current
paradigm for TLR ligands; as OspA is a triacylated lipo-
peptide, one may suspect it would be recognized by TLR2/1
heterodimers that recognize other known triacylated lipo-
peptides.
Studies have also examined the role of TLR expression in
Lyme disease. Salazar et al (2003) examined peripheral
blood and lesional aspirates of patients with erythema mi-
grans. Patients with erythema migrans were found to have
peripheral monocytes with higher surface expression of
TLR2 and TLR1. Furthermore, monocytoid DC demonstrat-
ed increased levels of TLR2 and TLR4 expression. Addi-
tionally, within erythema migrans lesions, macrophages and
monocytoid and plasmacytoid DCs all exhibited increased
expression of TLR1, 2, and 4. Since TLR expression levels
appear to be upregulated in this early stage of Lyme disease,
this suggests TLR may act early in the disease, attempting to
aid the host in containing the infection within the skin.
TLR as Therapeutic Targets
Treatment of viral skin diseases The imidazoquinolones,
imiquimod and R-848, were originally developed for use as
nucleoside analogs. These compounds do not have, how-
ever, nucleoside-like activity, and instead have established
utility as immune response modifiers. Imiquimod has been
identified as a TLR7 ligand, capable of inducing NFkB
through a MyD88-dependent pathway in macrophages
(Hemmi et al, 2002). As a result, imidazoquinolones induce
the production of several cytokines including IFN-a, tumor
necrosis factor (TNF)-a, and IL-12p40 from peripheral blood
monocytes, macrophages, and DC (Gibson et al, 1995).
These cytokine responses induced by the imidoquinolones
may then influence the host’s innate and adaptive immune
responses.
Early research on imiquimod focused on its ability to in-
duce IFN-a. As IFN-a is believed to protect cells from viral
infections, much research has focused on anti-viral prop-
erties of the drug. Anti-viral activity was first demonstrated
in guinea-pigs infected with HSV-2. Guinea-pigs inoculated
with HSV-2 were given imiquimod intravaginally for 5 d, and
these guinea-pigs demonstrated reduced vaginal viral rep-
lication and fewer recurrences of the infection (Harrison
et al, 1988). Further studies demonstrated that these imiqui-
mod-treated guinea-pigs had enhanced T cell memory to
the virus suggesting one mechanism for the drug’s ob-
served anti-viral properties (Harrison et al, 1994). In retro-
spect, this finding may be attributable to the fact that TLR
activation increases expression of co-stimulatory molecules
on DC, allowing DC to more effectively activate T cells.
Interestingly, in spite of all the research done with imiqui-
mod and HSV-2, imiquimod has rarely been used to treat
HSV-2 infections in humans. Instead, the drug was Food
and Drug Administration (FDA) approved to treat anogenital
HPV infections. One randomized, controlled trial examined
skin biopsies of HPV patients treated with 5% imiquimod
cream (Tyring et al, 1998). Examination of biopsies demon-
strating wart clearance revealed elevated IFN-a, IFN-b, IFN-
g, and TNF-a mRNA as well as decreased viral DNA and
mRNA. These results imply that an elevated cell-mediated
Th1 response may account for the clearing of HPV lesions,
and this Th1 response may be a consequence of imi-
quimod-induced cytokine production, and thus TLR7
activation.
In summary, several potential mechanisms for imiqui-
mod’s effectiveness in treating viral infections have been
proposed. Application of 1% imiquimod cream on the skin
of hairless mice demonstrated increased transcription of
IFN-a in the treated skin, indicating IFN-a may act locally as
an anti-viral agent (Imbertson et al, 1998). Imiquimod has
also been shown to promote maturation and migration of
LC to regional lymph nodes and to inhibit production of IL-4
and IL-5 by peripheral blood mononuclear cells, thus sup-
pressing the development of a Th2 adaptive immune re-
sponse (Wagner et al, 1999; Burns Jr et al, 2000; Suzuki
et al, 2000). The proposed imiquimod-induced suppression
of a Th2 adaptive immune response corroborates the finding
that HSV-2 antibody levels were reduced in imiquimod-
treated guinea-pigs (Harrison et al, 1994). Additionally,
imiquimod induces IL-12 production, and this promotes a
Th1 adaptive immune response that is necessary to elim-
inate intracellular pathogens such as viruses (Gibson et al,
1995). As cytokine production and Th1/Th2 skewing of
adaptive immunity are each results of TLR activation, it ap-
pears that many of the immunomodulatory effects demon-
strated by imiquimod occur as a result of TLR7 activation.
Also, as other TLR ligands such as lipoproteins and LPS
have demonstrated the ability to induce apoptosis, apop-
tosis may be one mechanism behind imiquimod’s effective-
ness (Meyer et al, 2003). The precise mechanism, however,
for imiquimod’s anti-viral activity in humans is not known.
Treatment of skin malignancies In addition to treating vi-
ral skin infections, there is recent research that investigates
imiquimod’s utility for treatment of skin cancers and pre-
cancerous lesions. There are studies and case reports that
treatment with 5% imiquimod cream has been effective in
treating basal cell carcinoma, actinic keratosis, Bowen’s
disease, and lentigo maligna (Bianchi et al, 2003a, b; Chen
and Shumack, 2003; Giannotti et al, 2003; Naylor et al,
2003; Stockfleth et al, 2003). Also, other TLR ligands such
as CpG (TLR9) and Taxol (TLR4) have been shown to kill
tumor cells and are being used for treatment of other can-
cers such as melanoma (Byrd-Leifer et al, 2001; Wang et al,
2002; Lonsdorf et al, 2003; Krieg, 2004). Since a cellular
immune response plays a role in suppressing the develop-
ment and growth of cancers, it is not too outrageous that an
immune response modifier such as imiquimod could be
used to treat cancers. Although it is too early to state if this
is a safe and effective alternative to other proven treat-
ments, however, these studies do highlight that the potential
applications for immune response modulators that act
through TLR are both broad and promising.
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Conclusions
TLR are crucial players in the innate immune response to
microbial invaders. These receptors are expressed on im-
mune cells, such as monocytes, macrophages, DC, and
granulocytes, and at sites of host–pathogen interaction such
as airway epithelium and skin. Host cells expressing TLR are
capable of recognizing conserved pathogen-associated mo-
lecular patterns, and their activation triggers signaling path-
ways that result in the expression of immune response
genes and cytokine production. The patterns of cytokines
produced may then instruct the type of adaptive immune
response the host will employ to fight the pathogen.
As TLR are instrumental in both launching innate immune
responses and influencing adaptive immunity, regulation of
TLR expression at sites of disease such as in leprosy, acne,
and psoriasis may be important in the pathophysiology of
these diseases. In some cases, as in leprosy, modulation of
TLR expression and activation may be protective and lessen
the severity of disease. TLR activation, however, may also
promote excessive inflammation and apoptosis contributing
to the pathology such as the nerve damage seen in leprosy
patients. Additionally, the recognition of P. acnes, a com-
mensal bacterium, through TLR2 induces inflammatory cyto-
kine production that may play a role in the pathogenesis of
the disease. Thus, TLR are vital players in infectious and in-
flammatory diseases, making them potential therapeutic tar-
gets. Indeed, the ability of TLR to combat disease has already
been harnessed through the development of drugs that act
as TLR agonists. To date, synthetic TLR agonists such as
imiquimod have found utility in treating viral pathogens and
skin cancers. Therefore, it seems possible that in the future
there may be drugs capable of blocking TLR-dependent in-
flammatory responses, and thus new treatment options for
inflammatory diseases such as acne and psoriasis.
The discovery of TLR and the development of drugs that
act through them are beginning to have an impact upon our
understanding and treatment of several cutaneous diseas-
es. In spite of their importance, however, relatively few
studies have addressed the role of TLR in skin. The ex-
pression of TLR on keratinocytes and their potential differ-
ential expression across the layers of the epidermis is still
unclear. Also, in addition to their role in infectious skin dis-
eases, TLR may play important roles in inflammatory skin
diseases such as acne, psoriasis, atopic dermatitis, lichen
planus, and lupus erythematosis, leaving this promising
area of study open for future investigations.
DOI: 10.1111/j.0022-202X.2004.23459.x
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